By
Drug Target Review2025-08-25T08:30:34
Researchers have found that mitochondrial dysfunction in the blood-brain barrier may drive neuropsychiatric disease in 22q11.2 deletion syndrome – and that a cholesterol drug could restore barrier function and ease symptoms.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-20T08:00:00Z
Contributor Dr Rahul Gupta, By Drug Target Review
2026-11-18T07:00:00Z
Contributor Dr Bryan McClellan and Dr William Matsui, By Drug Target Review
2026-11-17T09:31:00Z
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
2024-02-02T15:48:26
Sponsored by Bio-Techne
2025-03-19T15:00:00
Sponsored by Eurofins DiscoverX
2026-06-15T07:00:00
Contributor Professor Dipak Ramji, By Drug Target Review
2026-06-30T14:00:00
Sponsored by Analytik Jena GmbH + Co. KG
2024-01-24T12:52:38
Sponsored by BellBrook Labs
Site powered by Webvision Cloud